Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry
ConditionThoracic Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
MD Anderson Cancer Center
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
250 Participants
are grouped into 1 trial groupGroup A: Small Thoracic Tumors
Trial outcomes
Primary outcomes
1
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.
Time frame
Follow-up will continue per standard of care until death. Data will be collected when available in the patient's chart for a minimum of 5 years and a maximum of 10 years from ablation.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov